HRID618423

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

HCID21704

Adenine 9-beta-D-arabinofuranoside

C10H13N5O4

结构：CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H]([C@@H](C)NC)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O

HCID72395

Gentamicin C1

C21H43N5O7

HCID516892

Sodium Bicarbonate

CHNaO3

HCID178508933

未命名化合物

PRODUCTS

生成物

HCID21704

Adenine 9-beta-D-arabinofuranoside

C10H13N5O4

结构：NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1

HCID37542

Ribavirin

C8H12N4O5

HCID178508933

未命名化合物

PROCEDURE

实验过程

Ribavirin was obtained from ICN Pharmaceuticals, Costa Mesa, Calif. Acyclovir and 9β-D-arabinofuranosyladenine (ara-A) were Purchased from Sigma Chemical Co., St. Louis, Mo. Ribavirin, acyclovir and ara-A were prepared and diluted in MEM without serum, plus 0.18% NaHCO3, 50 μg gentamicin/ml. Oligonucleotides were diluted in the same solution.

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-b5a7d53774c7448f864860913d1955d0
来源数据集: uspto-grants-1999_09
DOI: 10.6084/m9.figshare.5104873.v1
专利: US05952490
来源说明: uspto-grants-1999_09

反应 SMILES

[CH:1]1[N:5]([CH2:6][O:7][CH2:8][CH2:9][OH:10])[C:4]2[N:11]=[C:12]([NH2:16])[N:13]=[C:14]([OH:15])[C:3]=2[N:2]=1.[C@@H:17]1([N:26]2[CH:34]=[N:33][C:32]3[C:27]2=[N:28][CH:29]=[N:30][C:31]=3[NH2:35])[O:23][C@H:22]([CH2:24][OH:25])[C@@H:20]([OH:21])[C@@H:18]1[OH:19].C([O-])(O)=O.[Na+].C[C@@H](NC)[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3OC[C@@](O)(C)[C@H]([NH:66]C)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)CC1>>[CH:1]1[N:5]([C@@H:6]2[O:7][C@H:8]([CH2:9][OH:10])[C@@H:18]([OH:19])[C@H:17]2[OH:23])[N:66]=[C:3]([C:14]([NH2:13])=[O:15])[N:2]=1.[CH:1]1[N:5]([CH2:6][O:7][CH2:8][CH2:9][OH:10])[C:4]2[N:11]=[C:12]([NH2:16])[N:13]=[C:14]([OH:15])[C:3]=2[N:2]=1.[C@@H:17]1([N:26]2[CH:34]=[N:33][C:32]3[C:27]2=[N:28][CH:29]=[N:30][C:31]=3[NH2:35])[O:23][C@H:22]([CH2:24][OH:25])[C@@H:20]([OH:21])[C@@H:18]1[OH:19]